The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care

Gil Bar-Sela, Marina Vorobeichik, Saher Drawsheh, Anat Omer, Victoria Goldberg, Ella Muller, Gil Bar-Sela, Marina Vorobeichik, Saher Drawsheh, Anat Omer, Victoria Goldberg, Ella Muller

Abstract

Background. Cancer patients using cannabis report better influence from the plant extract than from synthetic products. However, almost all the research conducted to date has been performed with synthetic products. We followed patients with a medicinal cannabis license to evaluate the advantages and side effects of using cannabis by cancer patients. Methods. The study included two interviews based on questionnaires regarding symptoms and side effects, the first held on the day the license was issued and the second 6-8 weeks later. Cancer symptoms and cannabis side effects were documented on scales from 0 to 4 following the CTCAE. The distress thermometer was used also. Results. Of the 211 patients who had a first interview, only 131 had the second interview, 25 of whom stopped treatment after less than a week. All cancer or anticancer treatment-related symptoms showed significant improvement (P < 0.001). No significant side effects except for memory lessening in patients with prolonged cannabis use (P = 0.002) were noted. Conclusion. The positive effects of cannabis on various cancer-related symptoms are tempered by reliance on self-reporting for many of the variables. Although studies with a control group are missing, the improvement in symptoms should push the use of cannabis in palliative treatment of oncology patients.

References

    1. .
    1. Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. British Journal of Anaesthesia. 2008;101(1):59–68.
    1. Wilson RI, Nicoll RA. Neuroscience: endocannabinoid signaling in the brain. Science. 2002;296(5568):678–682.
    1. .
    1. Carlson LE, Waller A, Groff SL, Bultz BD. Psychooncology. John Wiley & Sons; 2012. Screening for distress, the sixth vital sign, in lung cancer patients: effects on pain, fatigue, and common problems-secondary outcomes of a randomized controlled trial.
    1. Uritsky TJ, McPherson ML, Pradel F. Assessment of hospice health professionals’ knowledge, views, and experience with medical marijuana. Journal of Palliative Medicine. 2011;14(12):1291–1295.
    1. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management. 2010;39(2):167–179.
    1. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences. 2012;109(40):E2657–E2664.
    1. Cuttler C, McLaughlin RJ, Graf P. Mechanisms underlying the link between cannabis use and prospective memory. PLoS One. 2012;7(5, article e36820)
    1. .
    1. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain. 2012;13:438–449.
    1. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain. 2013;14:136–148.
    1. Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. European Journal of Cancer Care. 2008;17(5):431–443.
    1. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology. 2002;20(2):567–573.
    1. Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology. 2006;24(21):3394–3400.
    1. Carlson LE, Waller A, Groff SL, Zhong L, Bultz BD. Online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: randomised controlled trial of computerised vs personalised triage. British Journal of Cance. 2012;107(4):617–625.
    1. Engels FK, de Jong FA, Mathijssen RHJ, Erkens JA, Herings RM, Verweij J. Medicinal cannabis in oncology. European Journal of Cancer. 2007;43(18):2638–2644.
    1. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. Journal of Pain. 2008;9(6):506–521.
    1. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain. 2013;14:136–148.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren